Cue Biopharma, Inc.
NASDAQ:CUEBiotechnology
Healthcare
$14.10 +1.42%
+$0.38 today
- Market cap
- $102.43M
- Beta
- 2.53
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.06
52W Low $4.98High $41.42
Volume 0.21M
Average 0.74M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$21.69M
FY 2025 · Annual
Investing Cash Flow
$75,000.00
FY 2025 · Annual
+134.4% YoYFinancing Cash Flow
$26.29M
FY 2025 · Annual
+156.7% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (44.16M) | (53.01M) | (50.73M) | (40.67M) | (26.6M) |
| Depreciation & Amortization | (1.78M) | 1.81M | 3.44M | 2.35M | 958K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.52M | 9.5M | 8.18M | 6.85M | 4.74M |
| Change in Working Capital | (4.39M) | 356K | (934K) | (4.93M) | (3.3M) |
| Accounts Receivables | (1.73M) | 3.09M | (1.64M) | 753K | (6.5M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 520.4K | 83K | 770K | (678K) | 1.13M |
| Other Working Capital | (3.18M) | (2.81M) | (63K) | (5M) | 2.08M |
| Other Non-Cash Items | (26.13K) | (454K) | 90K | 74K | 2.51M |
| Operating Cash Flow | (38.84M) | (41.81M) | (39.96M) | (36.33M) | (21.69M) |
| Capital Expenditures | (913.04K) | (171K) | 0 | (66K) | (177K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 40K |
| Purchases of Investments | 0 | (29.45M) | 0 | 0 | (16.5M) |
| Sales of Investments | 10M | 5M | 25M | 0 | 16.5M |
| Other Investing Activities | 21.55K | 6K | 2K | 98K | 212K |
| Investing Cash Flow | 9.11M | (24.61M) | 25M | 32K | 75K |
| Debt Repayment | 0 | 10M | (2M) | (4M) | (4.5M) |
| Common Stock Issued | 17.38M | 39.3M | 13.39M | 14.22M | 30.79M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.85M | 4.36M | 473K | 18K | 0 |
| Financing Cash Flow | 19.23M | 53.66M | 11.86M | 10.24M | 26.29M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (10.5M) | (12.76M) | (3.1M) | (26.05M) | 4.68M |
| Free Cash Flow | (39.75M) | (41.98M) | (39.96M) | (36.4M) | (21.86M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$26.6M
+ D&A$958.0K
+ Stock-Based Comp$4.7M
+ Deferred Tax$0
- Working Capital-$3.3M
+ Other Non-Cash$2.5M
= Operating Cash Flow-$21.7M
- Capex-$177.0K
= Free Cash Flow-$21.9M
Analysis
FY2025 free cash flow is -$21.9M. FCF conversion is 82.2% of net income. Operating cash flow was -$21.7M, with capex of -$177.0K. The largest bridge item is Stock-Based Comp at $4.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 14, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 14, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 14, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 8, 2026 |
Does CUE generate free cash flow?
Cue Biopharma, Inc. (CUE) generated -$21.86M of free cash flow in fiscal 2025.
How much operating cash flow does CUE produce?
Operating cash flow was -$21.69M, before capital expenditures of $177,000.00.
Continue the stock analysis
Jump to another research area for this company.